Concord Biotech Ltd
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]
- Market Cap ₹ 11,642 Cr.
- Current Price ₹ 556
- High / Low ₹ 808 / 494
- Stock P/E 40.9
- Book Value ₹ 99.2
- Dividend Yield 0.68 %
- ROCE 17.1 %
- ROE 12.9 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 28.2%
Cons
- The company has delivered a poor sales growth of 11.3% over past five years.
- Company has high debtors of 159 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 239 | 276 | 340 | 436 | 512 | 616 | 713 | 853 | 1,017 | 1,200 | 1,055 | 1,170 | |
| Sales growth | +16% | +28% | +20% | +16% | +20% | +19% | +18% | -12% | +4% | |||
| 133 | 145 | 212 | 256 | 308 | 289 | 443 | 509 | 585 | 694 | 687 | 768 | |
| Operating Profit | 105 | 131 | 127 | 180 | 205 | 327 | 270 | 344 | 432 | 506 | 368 | 403 |
| OPM % | 44% | 48% | 37% | 41% | 40% | 53% | 38% | 40% | 42% | 42% | 35% | 34% |
| 11 | 8 | 36 | 17 | 32 | 14 | 23 | 37 | 37 | 44 | 52 | 46 | |
| Interest | 1 | 0 | 1 | 1 | 1 | 1 | 6 | 5 | 3 | 1 | 1 | 0 |
| Depreciation | 10 | 10 | 18 | 19 | 21 | 28 | 50 | 54 | 54 | 54 | 74 | 75 |
| Profit before tax | 106 | 129 | 144 | 178 | 214 | 313 | 238 | 322 | 413 | 495 | 345 | 374 |
| Tax % | 34% | 33% | 30% | 33% | 21% | 25% | 26% | 25% | 25% | 25% | 25% | |
| 70 | 87 | 100 | 118 | 169 | 235 | 175 | 240 | 308 | 372 | 259 | 279 | |
| EPS in Rs | 3.36 | 4.17 | 4.80 | 5.66 | 8.08 | 11.25 | 8.36 | 11.48 | 14.73 | 17.76 | 12.47 | 13.50 |
| Dividend Payout % | 22% | 25% | 0% | 21% | 22% | 0% | 3% | 30% | 30% | 25% | 30% |
(S): Standalone figures, shown where consolidated figures are not available.
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 11% |
| 3 Years: | 7% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 1% |
| 3 Years: | 1% |
| TTM: | -12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -4% |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 18% |
| 3 Years: | 18% |
| Last Year: | 13% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 268 | 329 | 585 | 673 | 761 | 990 | 1,094 | 1,280 | 1,516 | 1,802 | 2,007 | 2,065 |
| 35 | 36 | 22 | 9 | 52 | 86 | 62 | 32 | 10 | 3 | 2 | 2 | |
| 55 | 74 | 69 | 71 | 118 | 97 | 147 | 192 | 164 | 219 | 212 | 249 | |
| Total Liabilities | 367 | 448 | 685 | 763 | 941 | 1,183 | 1,313 | 1,514 | 1,701 | 2,034 | 2,232 | 2,327 |
| 104 | 110 | 189 | 230 | 240 | 546 | 573 | 593 | 575 | 795 | 789 | 771 | |
| CWIP | 19 | 70 | 3 | 19 | 141 | 18 | 74 | 173 | 211 | 51 | 79 | 112 |
| Investments | 42 | 43 | 151 | 229 | 199 | 141 | 74 | 137 | 246 | 335 | 491 | 533 |
| 202 | 225 | 343 | 285 | 361 | 477 | 592 | 611 | 668 | 854 | 873 | 911 | |
| Total Assets | 367 | 448 | 685 | 763 | 941 | 1,183 | 1,313 | 1,514 | 1,701 | 2,034 | 2,232 | 2,327 |
(S): Standalone figures, shown where consolidated figures are not available.
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 79 | 155 | 167 | 207 | 246 | 265 | 245 | 267 | ||||
| -42 | -114 | -195 | -112 | -158 | -155 | -160 | -143 | ||||
| -37 | -43 | 31 | -100 | -85 | -99 | -99 | -113 | ||||
| Net Cash Flow | 0 | -1 | 3 | -4 | 3 | 12 | -14 | 11 | |||
| Free Cash Flow | 79 | -1 | -38 | 52 | 101 | 180 | 134 | 172 | |||
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 101% | 100% | 74% | 99% | 92% | 85% | 70% | 100% |
(S): Standalone figures, shown where consolidated figures are not available.
Ratios
Consolidated / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 165 | 182 | 236 | 133 | 131 | 105 | 119 | 117 | 125 | 159 | 159 |
| Inventory Days | 276 | 321 | 381 | 310 | 312 | 503 | 434 | 430 | 331 | 286 | 485 |
| Days Payable | 108 | 129 | 210 | 112 | 201 | 152 | 185 | 190 | 150 | 135 | 151 |
| Cash Conversion Cycle | 334 | 374 | 407 | 331 | 242 | 456 | 368 | 357 | 306 | 310 | 493 |
| Working Capital Days | 195 | 209 | 275 | 177 | 159 | 177 | 161 | 152 | 166 | 193 | 230 |
| ROCE % | 37% | 25% | 32% | 21% | 26% | 28% | 28% | 17% |
(S): Standalone figures, shown where consolidated figures are not available.
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| API Share of Revenue % of total revenue |
|
||||||
| Capacity Utilization - Unit 1 (API, Dholka) % |
|||||||
| Domestic Share of Revenue % of total revenue |
|||||||
| Top 10 Customer Concentration % of total revenue |
|||||||
| New Customer Additions count |
|||||||
| Capacity Utilization - Unit 3 (API, Limbasi) % |
|||||||
| API Drug Master Files (DMFs) Filed count (cumulative) |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Allotment
- Concord Biotech allotted 10,46,16,204 bonus shares on November 4, 2026, in 1:1 ratio.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- Transcript of Q2 - FY27 Earnings call held on October 28, 2026
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Q2 and half-year FY27 earnings call recording hosted on company website.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Concord Biotech will attend a UBS non-deal roadshow in Singapore on 3-4 November 2026.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Press release - For the Second quarter and half year ended on September 30, 2026
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
Concalls
-
Nov 2026Transcript PPT REC
-
Aug 2026Transcript PPT REC
-
Jun 2026Transcript PPT REC
-
Feb 2026Transcript PPT
-
Nov 2025Transcript PPT
-
Aug 2025Transcript PPT
-
Jun 2025Transcript PPT REC
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Sep 2023Transcript PPT
Business Profile[1]
Concord Biotech is a pharmaceutical company headquartered in Ahmedabad, Gujarat, specializing in Active Pharmaceutical Ingredients (APIs) and formulations. The company is engaged in development and manufacturing of niche fermentation-based APIs and finished dosage formulations for domestic and international markets.